134150-01-9

Basic information

• Product Name: 4-Propylphenylboronic acid
• Synonyms: 4-PROPYLPHENYLBORIC ACID HPLC 98+%;4-n-Propylbenzeneboronic acid;4-Propylphenyboronic acid;(4-n-Propylphenyl)boronic acid;4-Propylphenylboronic acid (contains varying aMounts of anhydride);PropylPHenylboronic acid;AKOS BRN-0191;4-(PROPYL)BENZENEBORONIC ACID
• CAS NO: 134150-01-9
• Molecular Formula: C₉H₁₃BO₂
• Molecular Weight: 164.01
• EINECS: 1312995-182-4
• Product Categories: Boronic Acid series;Boronic acids;Aryl;Boronic Acids;Boronic Acids and Derivatives;Liquid crystal intermediates;blocks;BoronicAcids
• Mol File: 134150-01-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 89-97 °C(lit.)
• Boiling Point: 299.1 °C at 760 mmHg
• Flash Point: 134.7 °C
• Appearance: White to off-white/Crystalline Powder
• Density: 1.05 g/cm³
• Vapor Pressure: 0.000542mmHg at 25°C
• Refractive Index: 1.516
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 8.71±0.10(Predicted)
• CAS DataBase Reference: 4-Propylphenylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Propylphenylboronic acid(134150-01-9)
• EPA Substance Registry System: 4-Propylphenylboronic acid(134150-01-9)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• WGK Germany: 3
• Hazardous Substances Data: 134150-01-9(Hazardous Substances Data)

Usage

Description

4-Propylphenylboronic acid is an organic compound that serves as a versatile building block in organic synthesis, characterized by its white solid appearance.

Uses

Used in Pharmaceutical Industry:
4-Propylphenylboronic acid is used as a reactant for the palladium/carbon-catalyzed Suzuki coupling reactions, which are crucial for the preparation of biologically and pharmacologically active molecules. This makes it an essential component in the development of new drugs and therapeutic agents.
Used in Chemical Synthesis:
4-Propylphenylboronic acid is used as an intermediate in the synthesis of liquid crystals, which have a wide range of applications in various industries, including electronics and display technology.
Used in Organic Chemistry:
4-Propylphenylboronic acid is utilized in the Suzuki reaction, a widely employed method in organic chemistry for the formation of carbon-carbon bonds, particularly in the synthesis of complex organic molecules and natural products.

InChI:InChI=1/C9H13BO2/c1-2-3-8-4-6-9(7-5-8)10(11)12/h4-7,11-12H,2-3H2,1H3

Upstream product

• 588-93-2 p-bromo-n-propylbenzene 
• 109-72-8 n-butyllithium 
• 5419-55-6 Triisopropyl borate 
• 126261-84-5 1-iodo-4-n-propylbenzene 
• 2696-84-6 4-propylaniline 
• 10342-59-3 1-nitro-4-propyl-benzene 
• 17763-80-3 para-nitrophenyl triflate 
• 1359844-00-0 pinacol(4-propylphenyl)boronate 
• 121-43-7 Trimethyl borate 
• 2114-36-5 1-bromopropylbenzene 

Downstream Products

• 948044-01-7 3-fluoro-1-(4-propylphenyl)benzene 
• 137528-87-1 3,5-difluoro-4'-propylbiphenyl 
• 1186483-35-1 2-(2,3-Difluoro-phenyl)-5-[6-(4-propyl-phenyl)-pyridazin-3-ylmethyl]-5H-imidazo[4,5-d]pyridazine 
• 1104451-14-0 1-(4-(methylsulfonyl)phenyl)-4-(1-(4-propylphenyl)piperidin-4-yloxy)pyridin-2(1H)-one trifluoroacetate 
• 676545-65-6 2-(4-propylphenyl)-1,7,8-trifluoronaphthalene 

Relevant articles and documents

Design and synthesis of boronic acid inhibitors of endothelial lipase

Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL.

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.